Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Martin Dreyling, Réda Bouabdallah et al.|The Lancet|2016Cited by 401
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaMarie‐Hélène Delfau‐Larue, Eva Hoster, Wolfgang Hiddemann et al.|Blood|2015Cited by 157
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C. Kluin‐Nelemans, Martin Dreyling, Eva Hoster et al.|Journal of Clinical Oncology|2019Cited by 143
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Linmiao Jiang, Jan Walewski et al.|Journal of Clinical Oncology|2022Cited by 56